SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy

SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy

Background: SMAD4 is inactivated in 50–55% of pancreatic ductal adenocarcinomas (PDACs). SMAD4 loss of expression has been described as a negative prognostic factor in PDAC associated with an increased rate of metastasis and resistance to therapy. However, the impact of SMAD4 inactivation in patient...

Full description

Bibliographic Details
Main Authors: Marie-Lucie Racu, Dana Bernardi, Aniss Chaouche, Egor Zindy, Julie Navez, Patrizia Loi, Calliope Maris, Jean Closset, Jean-Luc Van Laethem, Christine Decaestecker, Isabelle Salmon, Nicky D’Haene
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Cancers
Subjects:
pancreas
pancreatic ductal adenocarcinoma
SMAD4
neoadjuvant therapy
prognosis
biomarker
Online Access:https://www.mdpi.com/2072-6694/15/15/3765

Internet

https://www.mdpi.com/2072-6694/15/15/3765

Similar Items